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Regulatory B cells restrict immune and inflammatory responses across a number of contexts. This 23 
capacity is mediated primarily through the production of IL-10. Here we demonstrate that the 24 
induction of a regulatory program in human B cells is dependent on a metabolic priming event driven 25 
by cholesterol metabolism. Synthesis of the metabolic intermediate geranylgeranyl pyrophosphate 26 
(GGPP) is required to specifically drive IL-10 production, and to attenuate Th1 responses. 27 
Furthermore, GGPP-dependent protein modifications control signalling through PI3Kδ-AKT-GSK3, 28 
which in turn promote BLIMP1-dependent IL-10 production. Inherited gene mutations in cholesterol 29 
metabolism result in a severe autoinflammatory syndrome termed mevalonate kinase deficiency 30 
(MKD). Consistent with our findings, B cells from MKD patients induce poor IL-10 responses and 31 
are functionally impaired. Moreover, metabolic supplementation with GGPP is able to reverse this 32 
defect. Collectively, our data define cholesterol metabolism as an integral metabolic pathway for the 33 
optimal functioning of human IL-10 producing regulatory B cells.   34 
 3
Introduction 35 
Immunosuppressive B cells form a critical component of the immune regulatory compartment 1,2. It is 36 
thought that their suppressive capacity derives mainly from their ability to produce IL-10, and in the 37 
absence of any lineage marker, this is considered a hallmark of regulatory B cells 3–6. Their functional 38 
importance has been well described in mouse models of disease, demonstrating a potent regulatory 39 
capacity across a number of contexts including infection, cancer, and autoimmune disease 3,7–10. 40 
Comparable suppressive activity has been demonstrated in human regulatory B cells in vitro, 41 
suggesting that these cells also contribute toward regulating inflammatory responses in humans 5,6. In 42 
support of this, IL-10 producing B cells have been demonstrated to be numerically depleted or 43 
functional impaired, ex vivo, in patients with inflammatory disease 5,11,12. 44 
 45 
Despite the importance of IL-10 production by B cells, relatively little is known about the molecular 46 
mechanisms that govern its expression. Typically, induction of a regulatory phenotype in both human 47 
and mouse B cells has been achieved through ligation of TLR9 or CD40 5,6,13. Downstream, PI3K and 48 
ERK signals appear to be important for IL-10 expression 14,15. This is in broad agreement with in vivo 49 
data from mouse models suggesting that both TLR and CD40 signals are required for the induction of 50 
IL-10 in response to inflammatory stimuli 3,13. However, precise details of the signaling cascades or 51 
cellular profiles underpinning the induction of a regulatory program in B cells are poorly understood. 52 
 53 
Control of immune cell metabolism is critical in regulating fundamental immunological processes 54 
16,17. However, in comparison to innate cell and T cell lineages, there has been relatively little work 55 
aimed at understanding the metabolic regulation of B cell biology 18–20. Furthermore, there is currently 56 
no understanding toward the metabolic requirements of regulatory B cells. An emerging concept from 57 
studies of regulatory T cells and M2 macrophages is their heightened reliance on lipid metabolism in 58 
comparison to the metabolic requirements of inflammatory immune cell lineages. Much of this work 59 
has focused on fatty acid oxidation, defining this as a central pathway that underpins polarization and 60 
effector functions in regulatory cells 21. In contrast, the contribution of cholesterol metabolism (the 61 
multi-step conversion of HMG-CoA to cholesterol) to immune function is less well characterized. Our 62 
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recent studies, as well as those of others, suggest that cholesterol metabolism plays a role in restricting 63 
inflammatory responses 22–24. These data are consistent with patients carrying mutations in the 64 
pathway, who develop severe and recurring autoinflammatory fevers, associated with dysregulated B 65 
cell responses, manifest by elevated serum immunoglobulin levels 25. 66 
 67 
Given the immunoregulatory associations with cholesterol metabolism, we set out to address its role 68 
in IL-10 producing B cells. In doing so, we reveal that cholesterol metabolism is a central metabolic 69 
pathway required for the induction of a regulatory phenotype in human B cells, and define the specific 70 
metabolic intermediate of the pathway that mediates critical signaling events for the induction of a 71 
regulatory B cell program. In vivo evidence for this specific metabolic requirement is provided by 72 
virtue of defective regulatory responses of B cells derived from patients with inherited defects in 73 
cholesterol metabolism. 74 
 75 
  76 
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Results 77 
Cholesterol metabolism drives regulatory B cell function 78 
Given that patients with dysregulated cholesterol metabolism generate severe systemic inflammation 79 
and hyperactive B cell responses, we investigated the role of cholesterol metabolism in regulatory B 80 
cell function (the metabolic pathway is depicted in Supplementary Figure 1). Consistent with previous 81 
observations, TLR9 ligation in human B cells induces a potent IL-10 response (Figure 1a-b, 82 
Supplementary Figure 2a-b), which mediates their regulatory phenotype 5,11. In agreement, TLR9 83 
activated B cells were able to suppress Th1 induction in CD4+ T cells in vitro (protocol outlined in 84 
Figure 1c). Neutralization of IL-10 resulted in a complete loss of suppression, confirming the 85 
dependence on IL-10 in mediating this function (Figure 1d). In line with this, concentrations of IL-10 86 
produced by B cells upon TLR9 stimulation (>1ngml-1, Figure 1b) were sufficient to directly suppress 87 
CD4+ T cell IFNγ expression (Supplementary Figure 2c). In contrast, pre-treatment of B cells with the 88 
HMG-CoA reductase inhibitor atorvastatin, which inhibits an early step of the cholesterol metabolic 89 
pathway, abrogated this suppressive capacity. Furthermore, supplementation of exogenous 90 
mevalonate reversed this defect, suggesting the requirement for a specific metabolite downstream of 91 
HMG-CoA (Figure 1d).  92 
 93 
The loss of suppressive capacity by IL-10 neutralization and HMG-CoA reductase inhibition 94 
indicated that cholesterol metabolism could be directly regulating IL-10 production. Indeed, inhibition 95 
of HMG-CoA reductase impaired the ability of B cells to produce IL-10, both at the mRNA and 96 
protein level (Figure 1e-f, Supplementary Figure 3a-b). Once again, and consistent with metabolic 97 
depletion downstream of HMG-CoA, exogenous mevalonate was able to reverse this defect (Figure 98 
1e-f). In contrast to IL-10, we observed a concurrent preservation in the inflammatory response, as 99 
determined by TNF and IFNγ protein, and IL6, and LTA gene expression (Figure 1g-h, Supplementary 100 
Figure 3c-d). Together, these data indicated that cholesterol metabolism was critical in mediating IL-101 
10 expression, and therefore the anti-inflammatory function of human B cells.  102 
 103 
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Cholesterol metabolism drives IL-10 independent of phenotype 104 
We next aimed to understand how cholesterol metabolism was able to mediate IL-10 production. 105 
Certain populations of human B cells have been proposed as primary producers of IL-10. The most 106 
well characterized of these are CD24hiCD27+ (B10) and CD24hiCD38hi B cells 5,6. In agreement with 107 
previous observations, we observed that all populations measured (B10, CD24hiCD38hi, naïve, 108 
memory, and plasmablast) contribute to the pool of IL-10 expressing cells to varying degrees after 109 
stimulation with CpG (IL-10+ cells ranging from 1-12% of B cell populations, Supplementary Figure 110 
4a-b). Furthermore, B10 and CD24hiCD38hi B cells produced higher levels (2-3-fold) of IL-10 in 111 
response to TLR9 stimulation (Supplementary Figure 4b). Acquiring the capacity to produce IL-10 112 
showed no dependence on proliferation, as IL-10 production was seen irrespective of proliferation 113 
state (Supplementary Figure 4c).  Following inhibition of HMG-CoA reductase we observed no 114 
change in frequencies of B cell populations, viability, or cell surface markers (HLA-DR, CD86, or 115 
CD40), excluding the possibility that perturbation of cholesterol metabolism was depleting specific B 116 
cell subsets that possess a greater propensity to express IL-10 (Supplementary Figure 4d-f). 117 
Furthermore, HMG-CoA reductase inhibition resulted in a 2-3-fold reduction in IL-10 expression 118 
irrespective of B cell population (either naïve, memory, B10, or CD24hiCD38hi, Supplementary Figure 119 
4g). Therefore, these data indicated a role for cholesterol metabolism in regulating IL-10 production 120 
that is shared across B cell populations, rather than an effect on specific populations. 121 
 122 
Cholesterol metabolism drives IL-10 via GGPP 123 
To more precisely understand the mechanistic control by cholesterol metabolism, we next sought to 124 
investigate if a specific pathway metabolite downstream of HMG-CoA was regulating IL-10. 125 
Cholesterol metabolism encompasses a number of metabolic pathways implicated in immune function 126 
including mevalonate, isoprenyl and sterol metabolism (Supplementary Figure 1), all of which are 127 
attenuated by HMG-CoA reductase inhibition to varying degrees. Given that defects in the isoprenyl 128 
branch have been demonstrated to result in hyperinflammatory responses in vivo 23,26, we investigated 129 
if isoprenylation was regulating IL-10. To this end, we targeted geranylgeranyltransferase (GGTase) 130 
and farnesyltransferase (FTase), enzymes known to post-translationally modify proteins with 131 
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geranylgeranyl pyrophosphate (GGPP) or farnesyl pyrophosphate (FPP) groups respectively 132 
(enzymes and metabolites outlined in Figure 2a). Inhibition of GGTase, but not FTase, substantially 133 
reduced TLR9-induced IL-10 production, indicating that geranylgeranyl dependent modifications 134 
regulate IL-10 expression (Figure 2b, Supplementary Figure 5a-b). In keeping with the effects of 135 
HMG-CoA reductase inhibition, inflammatory cytokine production was preserved (Figure 2c). 136 
Furthermore, we observed no or little effect on the proliferation, differentiation, and antibody 137 
production by B cells after TLR9 ligation in the presence of either atorvastatin or GGTi during longer 138 
cultures (5-7 days, Supplementary Figure 5c). In experiments to test GGTase specificity, we also 139 
observed that IL-10 was dependent on GGTase-I, but not GGTase-II, as inhibition of GGTase-II upon 140 
TLR9 ligation did not affect IL-10 expression (Supplementary Figure 5d).  141 
 142 
To support the notion of GGPP dependency, we depleted metabolites within the pathway with 143 
atorvastatin, and found that specifically supplementing the geranyl branch with exogenous GGPP 144 
prevented the blockade of IL-10 production (Figure 2d, Supplementary Figure 5e). In agreement with 145 
a specific effect of GGPP, supplementation with squalene – a metabolite downstream of the 146 
isoprenylation branch – was unable to rescue IL-10 production (Supplementary Figure 5f). Finally, to 147 
understand if cellular utilization of GGPP was dependent on the enzymatic activity of GGTase, we 148 
supplied cells with exogenous GGPP together with inhibition of GGTase. We found that GGPP was 149 
unable to rescue levels of IL-10 (Figure 2e), consistent with the idea that both GGTase activity and 150 
GGPP sufficiency are required for TLR9 induced expression of IL-10. 151 
 152 
GGPP regulates signaling through TLR9 153 
The most well characterized targets of isoprenylation are Ras superfamily proteins27,28. Ras-dependent 154 
pathways downstream of TLR9 include Raf-MEK-ERK and PI3K-AKT cascades (Figure 3a). 155 
Signaling through both pathways is critically required for IL-10 production, as inhibition of either 156 
pathway is sufficient to block TLR9-dependent IL-10 induction (Figure 3b-c). Therefore, we sought 157 
to address if activation of these pathways is dependent on GGPP. Following GGTase inhibition, AKT 158 
phosphorylation on Ser473 was severely impaired, whereas ERK phosphorylation was modestly 159 
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reduced at early timepoints (Figure 3d, quantification shown in Supplementary Figure 6a-b). 160 
Downstream, AKT restricts GSK3 activity through an inhibitory phosphorylation event targeting Ser9 161 
29. In keeping with the idea that GSK3 suppression is required for IL-10 production, chemical 162 
inhibition of GSK3 enhanced TLR9-induced IL-10 expression (Figure 3e). Blocking GGTase activity 163 
resulted in reduced Ser9 phosphorylation on GSK3. This indicated preserved activation of GSK3, and 164 
that GGTase activity negatively regulates GSK3, which in turn is necessary for IL-10 production 165 
(Figure 3f). We then examined if inhibition of GSK3 was sufficient to rescue an upstream 166 
perturbation of geranylgeranylation. Indeed, bypassing GGTase through GSK3 inhibition was able to 167 
fully rescue IL-10 expression, without affecting TNF (Figure 3g, Supplementary Figure 6c). Together 168 
these data suggest that following TLR9 engagement, IL-10 induction through AKT-GSK3, and 169 
possibly ERK, is dependent on GGTase activity. 170 
 171 
PI3Kδ regulates IL-10 expression in human and mouse B cells 172 
We next aimed to determine how geranylgeranyl-driven phosphorylation cascades regulate AKT-173 
GSK3 signaling. PI3K mediates Ras-dependent AKT signaling, which suggests that isoprenylation-174 
driven phosphorylation cascades through AKT are dependent on PI3K activity. Accordingly, pan 175 
inhibition of PI3K blocked expression of IL-10 upon TLR9 stimulation (Figure 4a). We found, by 176 
selective inhibition of either δ, α, or γ isoforms of PI3K, that IL-10 is primarily regulated through 177 
PI3Kδ downstream of TLR9 (Figure 4b). To further support the importance of PI3Kδ, we examined 178 
IL-10 production in splenic B cells derived from mice expressing either a hyperactive (E1020K) or 179 
catalytically inactive (D910A) PI3Kδ subunit. Following TLR9 activation, presence of the 180 
hyperactive PI3Kδ mutant resulted in 3-fold increased expression of IL-10, whereas the catalytically 181 
inactive PI3Kδ resulted in almost a complete loss of IL-10 production (Figure 4c). Furthermore, and 182 
in agreement with our previous observations, TNF production was preserved (Figure 4c). These data 183 
suggest that isoprenylation-dependent interactions between Ras and PI3Kδ are required for IL-10 184 
production, and likely underpin the regulatory function of B cells. 185 
 186 
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GGPP regulates IL-10 induction via BLIMP1 187 
Currently there is no defined transcription factor that regulates IL-10 in human B cells. Therefore, we 188 
sought to understand how IL-10 is transcriptionally regulated, and to clarify the role for GGPP in this 189 
process. Stimulation of B cells in the presence of actinomycin D indicated that a transcriptional event 190 
within the first 24 hours was necessary for IL-10 production (Supplementary Figure 7a). Therefore, 191 
we suspected that under conditions of GGTase inhibition, expression of a transcription factor 192 
necessary for IL-10 may be compromised. To test this, we performed RNA-sequencing on TLR9-193 
stimulated human B cells in the presence or absence of GGTase inhibition. Principal component 194 
analysis demonstrated that the main variation in the transcriptional profile of the cells was dependent 195 
on GGTase activity, as expected (Figure 5a, Supplementary Figure 7b). We then interrogated the list 196 
of differentially expressed genes (±1.5 fold, FDR<0.05) for those known or likely to encode human 197 
transcription factors (as defined by 30). Among the 73 differentially expressed transcription factors, 9 198 
have been shown to regulate IL-10 expression in other cell types (Figure 5b-d, Supplementary Figure 199 
7c), either through activation or repression (defined in 31). We decided to focus on BLIMP1 for two 200 
reasons. First, its transcript is enriched in IL-10+ human B cells 32. Secondly, interrogation of a mouse 201 
B cell ChIP- and RNA-seq data set 33 demonstrated that binding of BLIMP1 to the Il10 locus 202 
correlates with increased IL-10 expression (Supplementary Figure 7d). We first confirmed reduced 203 
expression of BLIMP1 protein upon GGTase inhibition (Supplementary Figure 7e), and consistent 204 
with previous data, we observed increased expression of BLIMP1 protein within the IL-10+ B cell 205 
population (Figure 5e). To more thoroughly address its role, we performed gene targeting experiments 206 
on BLIMP1 in primary human B cells. TLR9 stimulation strongly upregulated BLIMP1 expression in 207 
multiple B cell populations, including, unexpectedly, recently activated naïve and CD24hiCD38hi B 208 
cells (Figure 5f, Supplementary Figure 7f-g), whilst siRNA knockdown was able to reduce TLR9-209 
dependent protein level expression by ~60% (Figure 5g-h). In agreement with a central role in 210 
regulating IL-10, siRNA-mediated knockdown of BLIMP1 reduced IL-10 expression by 50-90%, 211 
whereas TNF production was preserved (Figure 5i). Together, these data demonstrate that BLIMP1 212 
regulates IL-10 in human B cells, and its expression is dependent on cholesterol metabolism for its 213 
provision of GGPP. 214 
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 215 
MKD patients generate poor regulatory B cell responses 216 
Our data demonstrated that cholesterol metabolism is essential for B cell derived IL-10 production. 217 
We therefore sought to validate our findings in the context of human inflammatory disease. To 218 
address this, we studied MKD patients, who carry a partial loss-of-function mutation in the 219 
mevalonate kinase gene, whose cognate substrate lies directly downstream of HMG-CoA in the 220 
metabolic pathway (highlighted in Supplementary Figure 1a). These patients present with a complex 221 
and severe autoinflammatory syndrome 25. We first compared peripheral regulatory B cells from 222 
MKD patients to age and sex matched healthy controls (Patient information in supplementary Figure 223 
8a). We observed similar frequencies of B10 cells, whereas CD24hiCD38hi B cells were reduced 224 
(Figure 6a-b). This is in line with a general shift from a naïve to memory like B cell phenotype in 225 
MKD patients (Supplementary Figure 8b). In longer term in vitro cultures, we observed that B cells 226 
from MKD patients possess a normal capacity to proliferate, differentiate, and to produce antibodies 227 
(Supplementary Figure 8c).  228 
 229 
We next examined if dysregulated cholesterol metabolism in patients with MKD leads to an inability 230 
to mount an IL-10 response, which could contribute to disease persistence or exacerbation. In line 231 
with this hypothesis, MKD patients generated poor IL-10 responses after stimulation through TLR9 232 
(30-70% reduction versus controls, Figure 6c), whilst TNF expression was enhanced in 2 of 4 donors 233 
(Supplementary Figure 8d). Interestingly, the defect in IL-10 production could be reversed by the 234 
addition of GGPP, indicating that at least in part, this defect was due to a relative deficiency of the 235 
isoprenyl metabolite (Figure 6c). As with our previous observations, IL-10 expression was reduced 236 
across all B cell phenotypes, including a ~3-fold reduction within B10 and CD24hiCD38hi B cells 237 
(Figure 6d, gating in Supplementary Figure 4a and d).  238 
 239 
We previously identified GSK3 as a key node in IL-10 production (Figure 3e-g). Therefore, we 240 
addressed if reduced IL-10 levels in MKD patients could be rescued through inhibition of GSK3, 241 
which would provide a rescue to signaling pathways further downstream of GGPP supplementation. 242 
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Indeed, GSK3 restriction in MKD patients was able to fully rescue IL-10 production (Fig. 6e). As 243 
with our previous data, supplementation with squalene was unable to restore IL-10 expression in 244 
MKD patients, supporting evidence that the IL-10 defect is specifically due to poor GGPP production 245 
(Supplementary Figure 8e). To examine the dependency of IL-10 expression on BLIMP1 in MKD 246 
patients, given our previous findings in healthy donor B cells, we analysed the capacity of MKD 247 
patients to upregulate BLIMP1 in response to TLR9 stimulation. In spite of the increased proportions 248 
of memory B cells present in MKD patients, we demonstrated a reduced capacity to induce BLIMP1 249 
compared to healthy B cells in 2 of 2 donors (Figure 6f), providing additional mechanistic data to 250 
explain why these patients show reduced B cell derived IL-10. 251 
 252 
We then addressed if the defect in IL-10 production from MKD patients was associated with a 253 
functional impairment. Indeed, we observed that MKD B cells were unable to suppress IFNγ 254 
production by autologous CD4+ T cells, when compared to B cells from healthy controls (Figure 6g). 255 
Moreover, pre-treatment of MKD B cells with exogenous GGPP prior to co-culture, was able to 256 
restore regulatory capacity in 2 of 2 donors tested (Supplementary Figure 8f), suggesting that a GGPP 257 
deficiency in MKD patients impairs both IL-10 expression and results in defective suppressive 258 
function. Given our B cell phenotype, we examined whether MKD imposed more a systemic defect 259 
on IL-10 producing immune cells we investigated whether T cell responses from MKD patients were 260 
also defective in IL-10 expression. In contrast to B cells, T cells were able to induce effective IL-10 261 
responses, alongside comparable levels of other cytokines including TNF, IFNγ, IL-2 and IL-17 262 
(Supplementary Figure 8g). 263 
 264 
Finally, to corroborate our results, we interrogated an independent dataset (GSE43553 taken from 34) 265 
that performed global gene expression analysis in ex vivo PBMCs from healthy controls (n=20) and 266 
MKD patients (n=8). Gene set enrichment analysis identified defective Ras (KRAS) and PI3K-Akt-267 
mTOR signaling pathways in MKD patients when compared to healthy donors, in line with our own 268 
observations (Figure 6h). Collectively, and consistent with our in vitro findings, these data suggest 269 
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that dysregulated cholesterol metabolism in vivo, as seen in MKD patients, results in impaired 270 






This study provides the first description of the metabolic requirements for IL-10 producing B cells, 276 
arguing for a central reliance on cholesterol metabolism. Our data point to a model in which synthesis 277 
of GGPP prior to stimulation permits transduction of receptor signaling cascades necessary for IL-10 278 
expression. As a consequence, the transcription factor BLIMP1 is induced, which then promotes IL-279 
10 gene expression. We propose that this has direct relevance in vivo, as IL-10 producing B cells from 280 
patients who carry mutations in the cholesterol metabolic pathway phenocopy our in vitro findings 281 
(Outlined in Figure 7). 282 
 283 
Investigations into B cell metabolism have focused primarily on either antibody production or 284 
activation induced metabolic reprogramming 18–20,35. As alluded to above, there was no understanding 285 
of the metabolic requirements for regulatory B cells. Here we demonstrate that cholesterol 286 
metabolism is critical in mediating the regulatory capacity of human B cells through its control of IL-287 
10. We have also previously shown that T cells require an intact cholesterol biosynthesis pathway to 288 
switch from inflammatory Th1 cells (IFNγ+IL-10-) to IFNγ+IL-10+ cells22, although this appears to be 289 
regulated by an alternative mechanism, as inhibition of isoprenylation did not affect this switch. 290 
Interestingly, cholesterol metabolism has been implicated in regulatory T cell function through a 291 
mechanism dependent on ICOS and CTLA-4, whilst having no effect on IL-10 expression 36. 292 
Although the authors did not explore this, we anticipate that regulatory T cells may also possess 293 
significant GGPP dependency, as regulatory T cell function is especially reliant on PI3Kδ activity 37. 294 
Therefore, whilst cholesterol metabolism appears to regulate different effector molecules between the 295 
cell types, it may be that regulatory T and B cells rely more heavily on cholesterol metabolism due to 296 
the necessity for potent GGPP-dependent PI3Kδ activity.  297 
 298 
Much of the experimental data regarding immunity and metabolism have suggested a paradigm in 299 
which the integration of metabolic pathways controlling cell fate arises as a direct consequence of 300 
immune cell activation. Based on the ability of cholesterol metabolism to control induction of a 301 
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regulatory program in human B cells by modulating TLR9 signaling, we propose that the 302 
programming of immune responses through cholesterol metabolism may differ in this regard. We 303 
propose that isoprenyl modifications constitute a metabolic pre-programming event. This pre-304 
programming requires the generation of GGPP prior to cellular stimulation (rather than upon or as a 305 
direct consequence of stimulation), that has the effect of fine-tuning signaling cascades. This notion of 306 
pre-programming is consistent with data showing the GGPP-dependent constitutive localization of 307 
Ras family proteins at the cell membrane and endosomes, and that blockade of cholesterol 308 
metabolism retains Ras in the cytoplasm 38,39. In other words, the state of signaling intermediates is 309 
preset by the state of cholesterol metabolism of the quiescent cell at any given point. 310 
 311 
Our finding that either GGPP deficiency or inhibition of its cognate enzyme GGTase was sufficient to 312 
block IL-10 production suggested that both the metabolite and its enzyme are absolutely required for 313 
the induction of a regulatory phenotype. Notably, inhibition of FTase was unable to inhibit IL-10 314 
production, likely due to the differing targets for geranylgeranylation and farnesylation 27. This 315 
suggests that cholesterol metabolism drives the anti-inflammatory function of B cells primarily 316 
through the synthesis of the isoprenyl group GGPP. These observations contrast with previous reports 317 
suggesting that isoprenylation largely mediates the restriction of pro-inflammatory cytokines, 318 
including TNF, IL-6, and IL-1β.  It should be noted however, that these data were derived from 319 
studies of mouse macrophages and intestinal epithelial cells 23,40,41. Nonetheless, whilst human B cells 320 
are known to co-express inflammatory cytokines TNF and IL-6 alongside IL-10 42, we saw no 321 
alteration in their capability to produce these upon blockade of GGTase. This suggests that pro-322 
inflammatory cytokine production relies less heavily on cholesterol metabolism. Our finding that 323 
cholesterol metabolism regulates PI3K signaling may somewhat explain this, given that PI3K can 324 
differentially regulate pro- versus anti-inflammatory cytokine production upon TLR ligation 43–45. 325 
 326 
We found that the mechanistic control of cholesterol metabolism revolves around its ability to 327 
regulate PI3Kδ-AKT signaling downstream of TLR9, although this is likely not the only target as we 328 
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also saw an effect on pERK activation. Although we documented expression of all isoforms of PI3K, 329 
we observed that PI3Kδ, to a greater extent than PI3Kα or PI3Kγ, contributed to IL-10 expression in 330 
human B cells upon TLR9 ligation. This finding is consistent with a recent observation identifying IL-331 
10 producing B cells as the primary pathological cell type in a model of activated PI3Kδ syndrome, 332 
driving Streptococcus pneumoniae persistence 14. We further suggest that GSK3 inactivation 333 
downstream of GGPP-dependent PI3Kδ-AKT signaling is also required for optimal IL-10 expression. 334 
Consistent with this, AKT-driven phosphorylation of GSK3 on Ser9 is known to differentially 335 
regulate cytokine production in monocytes 29. Moreover, we observed that reduced IL-10 expression 336 
induced in the context of defective isoprenylation could be rescued through inhibition of GSK3. In 337 
line with our findings, GSK3 inhibition in both innate cells 29 and Th1/2/17 cells 46 potentiates IL-10 338 
expression. This provides a common framework in all immune cells, whereby restriction of GSK3 339 
activity upon receptor ligation is necessary for IL-10 expression. 340 
 341 
Downstream of TLR9 ligation, BLIMP1 was shown to positively regulate IL-10 expression, 342 
suggesting its role as a transcriptional regulator of IL-10 in human B cells. Indeed, BLIMP1 has been 343 
previously demonstrated to control IL-10 induction in T cells47, and in a recent study in regulatory B 344 
cells48. Analysis of publicly available ChIP-seq datasets in both mouse and human B cells are in line 345 
with this finding, suggesting that IL-10 is a significantly enriched target of BLIMP1 33,49. This 346 
observation is reminiscent of recent work highlighting the role for BLIMP1-expressing regulatory 347 
plasmablasts and plasma cells in vivo 3,4,50,51, but also in humans ex vivo 51. Whilst this previous work 348 
provided a correlative link between BLIMP1 and IL-10, we suggest that BLIMP1 is a direct regulator 349 
of IL-10 in B cells. Therefore, it will be interesting in future work to further delineate a direct link and 350 
understand if there is a common mechanism regulating B cell derived IL-10 in both mouse and human 351 
B cells. Surprisingly, we observed expression of BLIMP1 in recently activated IgD+CD27- (naïve) B 352 
cells upon TLR9 stimulation (Supplementary Figure 7F). This has also been observed previously, 353 
where expression of BLIMP1 alongside a conformationally open chromatin arrangement in naïve B 354 
cells has been demonstrated52. This raises the question of whether BLIMP1 plays an earlier role in B 355 
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cell function at much earlier stages of activation, distinct from its more classical function linked to the 356 
development of terminally differentiated B cells. In addition to BLIMP1, several interesting 357 
candidates such as AHR and BATF were also identified in our screen, which warrant further 358 
investigation. 359 
 360 
To validate our findings in the context of human disease, we investigated patients with dysregulated 361 
cholesterol metabolism. MKD patients carry a mutation in the mevalonate kinase gene. As a 362 
consequence, their ability to convert mevalonate to mevalonate-5-phosphate is severely impaired. In 363 
keeping with our findings following perturbation of cholesterol metabolism in healthy B cells in vitro, 364 
we observed poor regulatory responses in B cell from these patients. This anti-inflammatory defect 365 
uncovered an unappreciated dimension to the spectrum of MKD. This included a reduced ability to 366 
produce IL-10, associated with a functional impairment in restricting T cell responses. In both cases, 367 
supplementation of GGPP was able to reverse this defect, suggesting that a lack of metabolic flux 368 
through the pathway might be contributing. Interestingly, GSK3 inhibition was also able to reverse 369 
the reduced IL-10 production observed in MKD patients, providing a specific signaling node 370 
downstream of GGPP deficiency that is dysregulated in patients. In agreement with GGPP deficiency, 371 
MKD patients have been demonstrated to accumulate unprenylated Ras proteins 53. Further 372 
characterization of MKD B cells demonstrated that, despite their increased frequencies of memory B 373 
cells, these cells do not effectively induce BLIMP1 expression in response to TLR9. This data is in 374 
line with our observations demonstrating that a deficiency in geranylgeranylation results in an 375 
inability to properly induce BLIMP1 expression. 376 
 377 
To date, the causative factor driving disease pathology has been defined as excessive inflammatory 378 
cytokine production, driven through increased macrophage driven IL-1β production 23,54, but also 379 
through the induction of a trained immunity phenotype driven by accumulated mevalonate 55. Here we 380 
also provide evidence that CD4+ T cells in MKD patients induce cytokine responses equivalent to 381 
those in healthy donors, suggesting this effect is intrinsic to B cells. Given the role of regulatory B 382 
cells in restricting cellular responses, we propose this B cell defect could contribute to the relapsing 383 
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and remitting nature of the disease. Moreover, it has been shown that B cell derived IL-10 is 384 
important in T follicular helper organization, and restricting excessive antibody responses via 385 
interaction with Tfh cells 56,57. It is therefore tempting to speculate that these patients generate 386 
inappropriately inflammatory B cell responses in lymphoid organs. This would go some way to 387 
explain the clinical observations in MKD patients who are typically diagnosed in early childhood with 388 
high circulating IgD and IgA levels 25.  389 
 390 
In summary, these results argue that cholesterol metabolism acts as a central metabolic pathway 391 
promoting an intrinsic anti-inflammatory program in B cells, driving IL-10 production and subsequent 392 




Cell isolation and culture 397 
Blood samples were obtained locally from healthy donors, and mevalonate kinase deficient patients 398 
were recruited from Royal Free Hospital NHS Foundation Trust. Human: Peripheral blood 399 
mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (Alere 400 
Technologies). Fresh CD19+ B cells and CD4+ T cells were subsequently isolated by magnetic cell 401 
sorting, based on CD19 and CD4 positive or CD4 negative selection (MACS, Miltenyi Biotech); 402 
purity was consistently >97%. Cells were cultured in RPMI-1640 (Sigma), 10% Fetal Bovine Serum 403 
(Sigma) with 2mM L-glutamine (Sigma), 0.1gL-1 sodium bicarbonate (Sigma), supplemented with 404 
100UmL-1 penicillin and 0.1mgmL-1 Streptomycin (PAA), and 10mM Hepes (PAA), in round bottom 405 
96-well Nunclon plates (Thermo Scientific) at 0.3 x 106 cells/well. B cells were activated with TLR9 406 
ligand CpG ODN 2006 (1μM, Invivogen), alongside recombinant human IL-2 (25Uml-1, Proleukin, 407 
Novartis) typically for 40 hours, or as indicated. Where indicated, CellTrace Violet (Thermofisher 408 
Scientific) labelling of cells was conducted as per manufacturer’s instructions, used at a final 409 
concentration of 2μM prior to stimulation. All inhibitors and metabolites were extensively titrated 410 
 18
prior to use, and reagent details are as follows: MK-2206 (Akt, 100nM), FTi-277 (Farnesyl 411 
transferase, 5μM), GGTi-298 or GGTi-2133 (Geranylgeranyl transferase-II, 5μM), Psoromic acid 412 
(Geranylgeranyl transferase-I, 0.1-10μM) CHIR-99021 (GSK3α/β, 5μM), atorvastatin (HMG-CoA 413 
reductase, 5μM), SCH772984 (ERK, 1μM), HS-173 (p110α, 1pM-1μM), IP-549 (p110α, 1pM-1μM), 414 
nemiralisib (p110δ, 1pM-1μM), (R)-mevalonic acid (250μM), Squalene (1-10μM), and 415 
geranylgeranyl pyrophosphate (2μM). Mouse: Total splenocytes were isolated from 8-15-week-old 416 
mice, red blood cells were lysed (Biolegend), and resulting single cell suspensions were cultured in 417 
the above media in flat bottom 48-well Nunclon plates (ThermoFisher), at 1 x 106 cells/well. Wild 418 
type, p110δ E1020K and p110δ D910A mice used in the study have been described previously58. B 419 
cells were stimulated with CpG ODN 1826 (1μM, Invivogen) in the presence of IL-2 (25Uml-1, 420 
Proleukin, Novartis) for 48 hours. Other ligands used for stimulation include: CD40L (6245-CL, 421 
1μgml-1, R&D Systems), LPS (10-500ngml-1, Invivogen), and IFNα (200-1000Uml-1). 422 
 423 
T and B cell co-culture 424 
Autologous CD4+ T and CD19+ B cells were isolated from healthy donors or MKD patients as 425 
described above. B cells were incubated overnight with CpG (1μM), IL-2 (25Uml-1), +/- atorvastatin, 426 
+/- mevalonic acid. In parallel, CD4+ T cells were stimulated with plate bound αCD3 and αCD28 427 
(both 1μgml-1, Biolegend). After 12 hours, B cells were washed twice, added to the T cells at a 1:1 428 
ratio, and cultured for 4 days +/- αIL10 antibody +/- isotype control (5μgml-1, both Biolegend). 429 
Assessment of the direct effect of IL-10 on human CD4 T cells was performed by plate bound 430 
αCD3/28 (1μgml-1) stimulated, cell trace violet labelled T cells, alongside incubation of the indicated 431 
concentration of IL-10 for 4 days. 432 
 433 
Flow Cytometry 434 
Antibodies used were as follows: IL-10-PE (dilution 1:800, JES3-19F1), TNF-BV421 (dilution 1:400, 435 
Mab11), IFNγ-PE/Cy7 (dilution 1:400, 4S.B3), CD20-AF647 (dilution 1:400, 2H7), CD24-BV605 436 
(dilution 1:400, ML5), CD27-FITC (dilution 1:200, M-T271), CD38-PE/Cy7 (dilution 1:400, HB-7), 437 
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IgD-BV421 (dilution 1:400, IA6-2), CD4-FITC (dilution 1:200, A161A1), HLA-DR-PerCP/Cy5.5 438 
(dilution 1:200, L243), CD86-BV421 (dilution 1:400, IT2.2), CD40-PE (dilution 1:400, 5C3): all 439 
Biolegend, pGSK3ser9-PE (dilution 1:10, REA436, Miltenyi), and BLIMP1-APC (dilution 1:10, 440 
646702, R&D Systems). For intracellular cytokine detection, cells were restimulated in the final 3 441 
(human) or 5 (mice) hours of culture with phorbol 12-myristate 13-acetate (50ngmL-1, Sigma) and 442 
ionomycin (500ngmL-1, Sigma) in the presence of Brefeldin A, and GolgiStop (both 1μlml-1, both BD 443 
Biosciences). For surface staining, cells were harvested and incubated with Fixable Viability Dye 444 
eFluor780 (dilution 1:4000, eBiosciences) for 15 minutes in phosphate buffered saline (PBS), 445 
followed by the appropriate volume of antibody diluted in 0.5% bovine serum albumin (BSA) in PBS 446 
for 20 minutes, all at 4°C. Cells were then washed and fixed in 3% paraformaldehyde (Electron 447 
Microscopy Sciences) for 15 minutes at room temperature. For intracellular cytokine staining, cells 448 
were incubated with the appropriate volume of antibody, diluted in 0.1% saponin in 0.5% BSA in 449 
PBS for 45 minutes at room temperature or 4°C overnight. For staining of transcription factors, or 450 
phospho-flow, FoxP3/Transcription factor buffer set was used, as per manufacturer’s instructions 451 
(eBiosciences). Staining using a secondary antibody against the primary was undertaken either at 452 
room temperature for 1 hour, or 4°C overnight. Cells were acquired using a BD LSRFortessa or 453 
FACSCanto II (BD Biosciences), and analysis conducted using FlowJo V.10.1 software (Tree Star 454 
Inc.). 455 
 456 
RNA extraction and qRT-PCR analysis 457 
Harvested cells were lysed in TRIzol (Ambion, Life Technologies), and stored at -20°C until RNA 458 
extraction by phenol-chloroform phase separation. Briefly, RNA was eluted by chloroform, and 459 
subsequently precipitated using ice cold isopropanol for 1 hour at -20°C. If necessary, RNA clean-up 460 
was conducted by reprecipitation of RNA in 0.5 volumes of 7.5M ammonium acetate, 2.5 volumes 461 
100% ice cold ethanol, and 1μl GlycoBlue overnight at -20°C. 40ng of RNA was added for reverse 462 
transcription, using qPCRBIO cDNA Synthesis Kit (PCR Biosystems) as per manufacturer’s 463 
instructions. qPCR was conducted using 7900HT Fast Real-Time PCR System (ThermoFisher 464 
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Scientific). Primers used were: IL10 (Hs00961622_m1), IL6 (Hs00174131_m1), or LTA 465 
(Hs04188773_g1), multiplexed with a VIC- labelled 18S probe (all Thermofisher Scientific) in PCR 466 
Biosystems mastermix.  467 
 468 
ELISA 469 
Sandwich ELISA was used to detect supernatant analytes. All cell free supernatants harvested at 470 
indicated time points were stored at -20°C until analysis. ELISAs for IL-10, IFNγ (both R&D 471 
systems, cat nos. DY217B and DY285B, respectively), TNF (Biolegend, cat no. 430201), or IgM 472 
(ThermoFisher Scientific, cat no. BMS2098) were conducted according to manufacturer’s protocols 473 
and detected on a Victor 1420 multilabel counter (Perkin Elmer) quantifying concentrations drawn 474 
from a standard curve on each plate. 475 
 476 
Western Blotting 477 
Antibodies used were as follows: BLIMP1 (dilution 1:1000, 646702, R&D Systems), pAktser473 478 
(dilution 1:1000, D9E), pERKThr202/Tyr204 (dilution 1:1000, D12.14.4E), and GAPDH (dilution 479 
1:5000, 14C10, all Cell Signaling Technologies). After culture, cells were harvested, washed in ice 480 
cold PBS, and lysates immediately extracted, or pellets were snap frozen on dry ice for 1 minute and 481 
kept at -80°C until lysis. Whole cell lysates were extracted using RIPA Buffer (Cell Signaling 482 
Technology) with 1X Protease inhibitor cocktail. Lysates were added to 4X Laemmli Sample Buffer 483 
(Bio Rad) with 10% 2-mercaptoethanol, and resolved on SDS-PAGE gels, transferred to PVDF 484 
membranes, blocked (Tris, 5% BSA, 0.05% Tween20) and probed with the desired antibody. 485 
Immunoblots were developed with anti-rabbit-HRP (Dako) secondary antibody, and proteins 486 
visualized by SuperSignal chemiluminescent reaction (Pierce) in a ChemiDoc station (BioRad). 487 
 488 
siRNA knockdown 489 
siRNA knockdown was conducted by Amaxa nucleofection using the nucleofector 2b machine, as per 490 
manufacturers protocol. siRNA knockdown was optimized, resulting in the used of 2-3 million cells 491 
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per condition, and 500nM of either BLIMP1 targeted siRNA (Silencer Select assay ID s1992) or 492 
scrambled control (Silencer Select Negative control, both from ThermoFisher Sceintific). Cells were 493 
electroporated using program U-015, resuspended in warm fully supplemented culture medium, and 494 
left to recover for 15 minutes before stimulation. Knockdown efficiency was determined by western 495 
blot at 40 hours post stimulation. 496 
 497 
RNA sequencing 498 
CD19+ B cells were stimulated with CpG (1μM) and IL-2 (25Uml-1) +/- GGTi-298 for 12 hours. RNA 499 
was isolated by column centrifugation using RNeasy Plus mini kit (with gDNA removal step) as per 500 
manufacturer’s instructions (Qiagen). Library preparation was completed using NEBNext Ultra 501 
Directional RNA Library Prep Kit for Illumina. Depletion of ribosomal RNA was performed using 502 
Next rRNA Depletion kit (New England BioLabs). RNA quality was confirmed by bioanalyser 503 
(Agilent 2100 Bioanalyzer G2938B), resulting in a mean RIN score of 8.1, ranging from 7.3-8.7. 504 
Paired-end sequencing was then conducted using the HiSeq 2500 platform (Illumina). Raw data was 505 
checked for quality using FASTQC. Processing of the raw data involving alignment (STAR) and 506 
annotation (hg19) were done using Partek. After annotation, TMM-normalised data were used for 507 
downstream statistical analysis using the exact test in the edgeR package. Inclusion criteria for 508 
significantly differentially expressed genes was a false discovery rate of <0.05 and a fold change of 509 
greater than 1.5x. Subsequent processing and visualization of the data was completed in RStudio or 510 
Morpheus (Broad Institute, Boston, MA). 511 
 512 
Gene set enrichment analysis 513 
Gene set enrichment analysis used on dataset GSE4355334 was conducted with GSEA v4.0.2 (Broad 514 
Institute). Gene expression data was used from 20 healthy controls (GSM1065214 to GSM1065233) 515 
and 8 MKD patients (GSM1065234 to GSM1065241). Gene sets were compared to the gene set 516 
database h.all.v7.0.symbols.gmt [Hallmarks], using 1000 permutations, the ‘weighted’ enrichment 517 




All statistical analysis was conducted using GraphPad Prism v7.0 (GraphPad, San Diego, CA, USA). 521 
Paired data was analysed through either two-way ANOVA with Dunnett’s test for multiple 522 
comparisons, or Freidman’s test with Dunn’s test for multiple comparisons. Unpaired data was 523 
assessed through ANOVA with Tukey’s test for multiple comparisons. Finally, two-group 524 
comparison was performed either through unpaired or paired T test. A P value of < 0.05 was 525 
considered statistically significant, and all statistically significant values are shown. 526 
 527 
Study approval 528 
Blood samples were obtained locally from healthy donors, and mevalonate kinase deficient patients 529 
were recruited from Royal Free Hospital NHS Foundation Trust, London, UK or National Human 530 
Genome Research Institute/Inflammatory Disease Section, Bethesda, USA. Written informed consent 531 
was received from all healthy donors and patients used in this study, approved by the Bromley 532 
Research Ethics Committee (REC06/Q0705/20) and by the NIDDK/NIAMS Institutional Review 533 
Board. Animal experiments were performed according to the Animals (Scientific Procedures) Act 534 
1986, license PPL 70/7661 and approved by the Babraham Institute Animal Welfare and Ethics 535 
Review Body. 536 
 537 
Data Availability 538 
Sequence data generated in this study have been deposited in GEO under the accession code 539 
GSE150245 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150245]. Publicly available 540 
datasets used for analysis are available at GEO under the accession codes GSE43553 541 
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43553] (used in GSEA analysis), and 542 
GSE71698 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71698] (used for ChIP 543 
and RNA-seq analysis). 544 
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Figure. 1. Cholesterol metabolism drives regulatory B cell function. a-b. Kinetics of IL10 mRNA transcript 707 
(a) and IL-10 secreted protein (b) expression at various time points in human B cells after TLR9 stimulation (n=4 708 
for mRNA or n=4-5 for protein). IL10 mRNA was measured by qRT-PCR, and calculated relative to 18S. c. 709 
Schematic protocol for the co-culture for T and B cells. Briefly, human B cells were stimulated through TLR9 ± 710 




 T cells for 4 days ± αIL-10 antibody. d. IFNγ production in human CD4
+
 T cells after co-culture with 712 
autologous TLR9-activated B cells (n=6, pval = 0.03 and 0.02). IFNγ suppression was calculated by: ((x-y)/x)*100 713 
where x = IFNγ production by T cells alone, y = IFNγ production in co-cultured T cells. e. IL-10 expression in 714 
human B cells after stimulation through TLR9 ± AT ± MA (n=7, pval = 0.003). f. IL-10 mRNA expression over 715 
time in human B cells after stimulation through TLR9 ± AT ± MA (n=4). g. TNF expression in human B cells after 716 
stimulation through TLR9 ± AT ± MA (n=7). h. IL6 or LTA mRNA expression, relative to 18S, in human B cells 717 
after stimulation through TLR9 ± AT (n=4). Each data point represents individual donors. All data presented are 718 
mean ± SD. Statistical testing in all figures was done by a Friedman’s test with Dunns’s multiple comparisons 719 
test, or for (f) a mixed-effects model with Dunnett’s multiple comparisons test. *P<0.05, **P<0.01, ***P<0.001, 720 
and all significant values are shown 721 
 722 
Figure. 2. Cholesterol metabolism drives IL-10 via GGPP. a. Schematic diagram showing key metabolites and 723 
enzymes of the isoprenylation route in cholesterol metabolism. b-c. IL-10 (b) and TNF (c) expression in human B 724 
cells after stimulation through TLR9 ± geranylgeranyl transferase inhibition (GGTi, GGTi-298) ± farnesyl 725 
transferase inhibition (FTi, FTi-277) (n=5 for IL-10, pval = 0.001; n=6 for TNF). d. IL-10 expression in human B 726 
cells after stimulation through TLR9 ± atorvastatin (AT) ± geranylgeranyl pyrophosphate (GGPP) (n=4, pval = 727 
0.009). e. IL-10 expression in human B cells after stimulation through TLR9 ± GGTi ± GGPP (n=4, pval both 728 
0.03). Each data point represents individual donors. All data presented are mean ± SD. Statistical testing in all 729 
figures was done by a Friedman’s test with Dunns’s multiple comparisons test. *P<0.05, **P<0.01, and all 730 
significant values are shown. 731 
 732 
Figure. 3. GGPP regulates signalling through TLR9. a. Schematic of Ras-dependent signalling cascades 733 
downstream of TLR9. b-c. IL-10 expression in human B cells stimulated through TLR9 ± inhibition of (b) AKT 734 
(AKTi, MK-2206) or (c) ERK (ERKi, SCH772984) (n=4, pval = 0.005, and 0.001). d. Phosphorylation of AKT 735 
(ser473) or ERK1/2 (Thr202/Tyr204) over time in human B cells upon stimulation through TLR9 ± inhibition of 736 
geranylgeranyl transferase (GGTi) (representative of n=3). e. IL-10 expression in human B cells stimulated 737 
through TLR9 ± inhibition of GSK3 (GSK3i, CHIR-99021) (n=9, pval<0.001). f. Phosphorylation of GSK3 (ser9) 738 
over time in human B cells upon stimulation through TLR9 ± inhibition of geranylgeranyl transferase (GGTi-298), 739 
relative to unstimulated controls (n=4, pval = 0.02). g. IL-10 and TNF expression in human B cells stimulation 740 
through TLR9 ± GGTi ± GSK3i (n=7, pval = 0.0001). Each data point represents individual donors. All data 741 
presented are mean ± SD. Statistical testing in figures in (b), (c), and (e) was done by a paired t test, (f) using a 742 
twoway ANOVA with Sidak’s multiple comparisons test, and (g) by Friedman’s test with Dunns’s multiple 743 
comparisons test **P<0.01, ***P<0.001, ****P<0.0001 and all significant values are shown. 744 
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 745 
Figure. 4. PI3Kδ regulates IL-10 expression in human and mouse B cells. a. IL-10 expression in human B 746 
cells stimulated through TLR9 ± pan inhibition of PI3K (PI3Ki, ZSTK474) (n=4, pval = 0.008). b. IL-10 expression 747 
in human B cells stimulated through TLR9 ± inhibitors for specific family members of PI3K: these being δ 748 
(Nemiralisib), γ (IP-549), or α (HS-173), over a range of concentrations (n=4). c. IL-10 and TNF expression in 749 
mouse B cells after stimulation through TLR9. Mice used were wild type (WT), hyperactive PI3Kδ (E1020K), or 750 
catalytically inactive PI3Kδ (D910A) (n=3, pval = 0.002 and <0.0001). Each data point represents individual 751 
donors or mice. Data presented are mean ± SD. Statistical testing in figures in (a) was done by a paired t test, or 752 
in (c) by a one-way ANOVA with Dunnet’s multiple comparisons test. **P<0.01, ****P<0.0001 and all significant 753 
values are shown. 754 
 755 
Figure. 5. GGPP regulates IL-10 induction via BLIMP1. a. Principal component analysis of human B cells after 756 
stimulation through TLR9 ± geranylgeranyl transferase inhibition (GGTi), with analysis performed on total 757 
normalised counts generated from RNA-sequencing data, before statistical analysis (n=7). b. Workflow for the 758 
identification of putative IL-10 transcription factors. First, differentially expressed genes were cross referenced 759 
with known or likely human transcription factors, and the subsequently identified differentially expressed 760 
transcription factors were cross referenced with previously validated IL-10 transcription factors in either 761 
macrophages or T cells. Differentially regulated IL-10 transcription factors are shown in (c) and all differentially 762 





 B cells after stimulation through TLR9 (n=6, pval = 0.003). f. Western blot showing BLIMP1 764 
expression in human B cells either in unstimulated or stimulated through TLR9 (CpG) after 40 hours 765 
(representative of three independent experiments). g-h. Western blot showing expression of BLIMP1 in human B 766 
cells after stimulation of TLR9 and nucleofection with either a scrambled control (Scr) or BLIMP1 siRNA (n=5, 767 
pval = 0.001). i. IL-10 and TNF expression in human B cells stimulated through TLR9 after nucleofection with 768 
either Scr or BLIMP1 siRNA (n=6 for flow cytometry, pval = 0.002; and 5 for ELISA, pval = 0.009). Each data 769 
point represents individual donors. All data presented are mean ± SD where average values are shown. 770 
Statistical analysis in all figures was done using a paired t test. **P<0.01, ***P<0.001 and all significant values 771 
are shown.  772 
 773 









 regulatory B cells in mevalonate kinase deficient (MKD) patients, compared to age and sex 775 
matched healthy donors (HD). c. IL-10 expression in MKD patients and HD after stimulation through TLR9 ± 776 




, naïve, and memory 777 
 31
populations, showing the differential contribution of B cell phenotypes to IL-10 production (n=3, pval = <0.0001, 778 
0.002, and 0.01). e. IL-10 expression in MKD patients and HD after stimulation through TLR9 ± GSK3i (CHIR-779 
99021). f. BLIMP1 expression in naïve and memory HD or MKD patient B cells after stimulation through TLR9 780 
(n=2). g. IFNγ production in human CD4
+
 T cells of healthy controls and MKD patients after co-culture with 781 
autologous TLR9-activated B cells. Protocol is outlined in Fig. 1C. h. Gene set enrichment analysis conducted on 782 
gene expression profiles from an independent dataset (GSE43553) on PBMCs ex vivo in MKD patients (n=8) or 783 
HD (n=20). Heatmap shows all genes involved in ‘Hallmark’ PI3K-Akt-mTOR gene set collection from MSigDB, 784 
and their relative expression in MKD vs HD. Enrichment plots show PI3K-Akt-mTOR and KRAS DN (genes 785 
downregulated by KRAS activation) in MKD vs HD. Each data point represents individual donors. All data 786 
presented are mean +/- SD where average values are shown. Statistical analysis in (d) was conducted using a 787 
paired t test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 and all significant values are shown.  788 
 789 
Figure 7. B cell IL-10 regulation by GGPP. IL-10 production by B cells is regulated by cholesterol metabolism 790 
though geranylgeranyl pyrophosphate, controlling signalling cascades and BLIMP1 induction downstream of 791 
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